123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 , with a K i value of 0.65 μMForm:SolidIC50& Target:Ki: 0.65 μM (EPHA4)
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 , with a K i value of 0.65 μMForm:SolidIC50& Target:Ki: 0.65 μM (EPHA4)
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 , with a K i value of 0.65 μMForm:SolidIC50& Target:Ki: 0.65 μM (EPHA4)
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 , with a K i value of 0.65 μMForm:SolidIC50& Target:Ki: 0.65 μM (EPHA4)
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 , with a K i value of 0.65 μMForm:SolidIC50& Target:Ki: 0.65 μM (EPHA4)
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 , with a K i value of 0.65 μMForm:SolidIC50& Target:Ki: 0.65 μM (EPHA4)
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC 50 value of 40 nM in cellIn VitroALW-II-49-7 (compound 9) exhibits selectivity profile of binding to a set of kinases including b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2,
BT5528 is a bicyclic peptide toxin conjugate, an EphA2 activator. BT5528, made up of a bicyclic peptide and Auristatin E ( HY-15582 ), is derivated from BCY6099. BT5528 shows potent anti-tumor activity without bleeding or coagulation toxicity in
BT5528 is a bicyclic peptide toxin conjugate, an EphA2 activator. BT5528, made up of a bicyclic peptide and Auristatin E ( HY-15582 ), is derivated from BCY6099. BT5528 shows potent anti-tumor activity without bleeding or coagulation toxicity in